Valvular & structural heart diseaseCohort study
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
- Target trial emulation using retrospective electronic medical record data
- multicenter
- observational
- Median SGLT2i duration 0.9 years
Authors' conclusion
This retrospective, multicenter, observational study suggests that SGLT2i may slow the progression of nonsevere AS.
Study context
- Population
- Patients with native aortic valve sclerosis or nonsevere aortic stenosis (AS) with ≥12 months of echocardiographic follow-up, Yale New Haven Health System, January 2016 to September 2022; excluded eGFR <30 mL/min/1.73 m² or SGLT2i initiated >1 year before index echocardiogram
- Participants
- 458 vs 11,240
- Exposure
- SGLT2 inhibitor initiation vs no SGLT2 inhibitor
- SGLT2in = 458
- No SGLT2in = 11,240reference
- Outcome
- Progression to severe AS
Main finding
As reported in the abstract
Hazard ratio
0.61
95% CI 0.39–0.94
P = 0.03
SGLT2i vs No SGLT2i
HR 0.61 (95% CI 0.39–0.94); P = 0.03
Observational data: associations, not effects.
Further findings
| Outcome | HR |
|---|---|
| Progression to severe AS by SGLT2i duration (>3, 6 and 12 months) — SGLT2i vs No SGLT2i · >3 months | 0.54 |
| Progression to severe AS by SGLT2i duration (>3, 6 and 12 months) — SGLT2i vs No SGLT2i · >6 months | 0.48 |
| Progression to severe AS by SGLT2i duration (>3, 6 and 12 months) — SGLT2i vs No SGLT2i · >12 months | 0.27 |
Original publication
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovasc Interv. Published 19 February 2025. doi:10.1016/j.jcin.2024.11.036
Summarised from the published abstract; every number is checked against it